<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564393</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO09-PD / MucoNETs</org_study_id>
    <nct_id>NCT02564393</nct_id>
  </id_info>
  <brief_title>Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis</brief_title>
  <acronym>MucoNETs</acronym>
  <official_title>Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is defined in 3 stages of in vitro assays :&#xD;
&#xD;
      Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors.&#xD;
&#xD;
      This is a transversal study in which we compare :&#xD;
&#xD;
        -  Producing NETs (DNA and proteases ) by neutrophils purified from sputum and blood of&#xD;
           patients&#xD;
&#xD;
        -  Producing NETs (DNA and proteases ) by purified neutrophils in the blood of patients and&#xD;
           blood of control subjects&#xD;
&#xD;
      Phase 2: Mechanisms of activation of NETs secretory pathways . This phase will identify&#xD;
      receptors (TLR ) involved in the secretion of NETs and analyze the involvement of dependent&#xD;
      transduction pathways calcium and PKC . It will be performed on control blood neutrophils.&#xD;
&#xD;
      Phase 3: Analysis of cell death ( NETose )&#xD;
&#xD;
      This is a transversal study that will analyze :&#xD;
&#xD;
      the mode of cell death of neutrophils purified blood and sputum of patients and control blood&#xD;
      neutrophils by flow cytometry and transmission electron microscopy .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the DNA concentration secreted into the extracellular environment neutrophil activated</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Adult with cystic fibrosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pathophysiological study comparing a &quot; Cystic fibrosis &quot; group to a control group (adults)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients :&#xD;
&#xD;
          -  Men or women over 18&#xD;
&#xD;
          -  Patients with mucoviscidose in stable condition, i.e. not having presented an acute&#xD;
             push of bronchopulmonary attack requiring a antibioth√©rapie or a hospitalization for&#xD;
             treatment of its disease during the 2 previous weeks&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Volunteers :&#xD;
&#xD;
          -  Men or women over 18&#xD;
&#xD;
          -  Without respiratory antecedent nor known respiratory pathology&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients :&#xD;
&#xD;
          -  In exclusion period of an other study&#xD;
&#xD;
        Volunteers :&#xD;
&#xD;
          -  In exclusion period of an other study&#xD;
&#xD;
          -  Antibiotic treatment and/or anti-inflammatory drug (AINS or corticoids) in the 2 weeks&#xD;
             before inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

